Related Experiment Videos

Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma

Mahmoud S Ahmed1, Fathi T Halaweish

  • 1Department of Chemistry and Biochemistry, South Dakota State University , Brookings, SD , USA.

Journal of Enzyme Inhibition and Medicinal Chemistry
|February 2, 2013
PubMed

Insights

Cucurbitacins (Cucs) show promise in inhibiting melanoma cell growth by targeting B-RAF and MEK1 kinases. These natural compounds offer a potential new avenue for cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Kinase inhibition is a validated therapeutic strategy for malignancies.
  • B-RAF mutations are prevalent in melanoma, driving tumor progression.
  • Cucurbitacins (Cucs) are known inhibitors of signal transducer and activator of transcription 3 (STAT3).

Purpose of the Study:

  • To evaluate Cucurbitacins (Cucs) as potential inhibitors of B-RAF and MEK1 kinases.
  • To assess the efficacy of Cucs against B-RAF-mutated melanoma cell lines.
  • To explore Cucs as a novel therapeutic strategy for melanoma.

Main Methods:

  • Virtual screening was employed to identify potential lead Cuc compounds.
  • In vitro assays were performed on A-375 and Sk-Mel-28 melanoma cell lines.
  • Enzyme-linked immunosorbent assays (ELISA) were used to measure ERK phosphorylation inhibition.

Main Results:

  • A series of natural Cucs demonstrated significant activity against Sk-Mel-28 and A-375 cell lines.
  • Cucs exhibited potential inhibition of both total and phosphorylated ERK.
  • The study identified specific Cucs with promising anti-melanoma activity.

Conclusions:

  • Cucurbitacins (Cucs) show potential as inhibitors of the B-RAF/MEK/ERK signaling pathway in melanoma.
  • Natural Cucs represent a viable candidate class for developing novel melanoma therapeutics.
  • Further research into Cucs could lead to new treatments for B-RAF-mutated melanoma.

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...